- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our monthly e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Authors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- David Thomas
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Timothy Coetzee
- Tracy Cooley
Tags
Biofuel Technology Benefits of biotech crops renewable fuel standard Food and Fuel Climate Change global food crisis Plant biotechnology ethanol agriculture BIO indirect land use change Food Animal biotechnology biotechnology greenhouse gas emissions Partnering BIO Investor Forum Greenhouse Gas Emission One-on-One's
Tag Archives: healthcare
Podcast: Dr. Hervé Tettelin on vaccine development
Dr. Tettelin, with the University of Maryland School of Medicine in the Institute for Genome Sciences, discusses his research in reverse vaccinology and as a pioneer of the pan-genome concept. He also discusses how DNA sequencing is evolving and how that impacts vaccine development. Download the podcast
Casting Call for “Rare Disease Chasers” – A New Reality TV Series
Are you a medical expert who works on finding, diagnosing and treating people with rare diseases? Are you interested in starring on a reality TV series? The executive management of the Global Healthy Living Foundation launched a nation-wide search for physicians, researchers and other medical experts who may be interested in starring in a show called “Rare Disease Chasers” on The Learning Channel (TLC) network. The series will follow a team of medical experts each Read More >
Intellectual Property problems for personalized medicine
Amid growing interest in personalized medicine that stands to provide patients with better care at reduced costs, legal battles over gene patents ensue, threatening the viability of widespread implementation. On this topic authors Jennifer Gordon, Steve Lendaris and Anna Volftsun (layers at Baker Botts LLP) wrote a very interesting opinion article for The Scientist on the topic. They also examine the barriers to personalized medicine, including a pending decision in the Myriad Genetics case, and Read More >
AUTM’s 2010 Better World Report Highlights
AUTM released their Better World Report for 2010 highlighting academic innovations commercially developed through technology transfer that are improving the quality of life. Here is a quote from their press release. A device that allows the blind to ―see‖ via electrical pulses applied to the tongue…a collagen scaffold to treat damaged joints…a new vaccine to prevent shingles…an artificial lung that provides patients with both mobility and comfort during treatment…a program that vastly improves literacy among Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Association of Technology Transfer Managers, AUTM, Bayh-Dole, BIO, biotechnology, economic development, federally funded research, Global Health, government funded research, healthcare, Licensing technology, modern medicine, new drug development, NIH, patents, Research and Development, Senator Birch Bayh, Senator Dole
Tags: Association of Technology Transfer Managers, AUTM, Bayh-Dole, BIO, biotechnology, economic development, federally funded research, Global Health, government funded research, healthcare, Licensing technology, modern medicine, new drug development, NIH, patents, Research and Development, Senator Birch Bayh, Senator Dole
Don’t Be Afraid of “Frankenfish”
The Wall Street Journal ran on September 23, 2010, an op-ed authored by BIO President and CEO Jim Greenwood about FDA’s pending approval of a genetically engineered salmon. This salmon can help meet the growing demand for protein-rich food without depleting wild fish stocks. Right now, the government is deciding whether it’s safe for us to eat genetically engineered salmon. The fish, called AquAdvantage, is being developed by a Massachusetts biotech firm and is in Read More >
